Trial Profile
Phase I double-blind randomized control study evaluate safety and immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 recombinant malaria vaccine (PfCP-2.9) adjuvant with montanide ISA 720 compared to montanide ISA 720 alone in adult volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2020
Price :
$35
*
At a glance
- Drugs Malaria vaccine (Primary) ; Montanide ISA-720
- Indications Falciparum malaria; Malaria
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Shanghai Wanxing Bio-Pharmaceutical
- 09 Dec 2008 Results were published in Vaccine.
- 04 Dec 2006 New trial record.